Name plasminogen activator, urokinase caption PLAU image width HGNCid 9052 Symbol PLAU AltSymbols ... q Band 24 LocusSupplementaryData Urokinase trade name Abbokinase , also called urokinase type plasminogen activator uPA , is a serine protease EC number 3.4.21.73 . Urokinase was originally isolated ... degradation. This links urokinase to vascular diseases and cancer. Molecular characteristics Urokinase ... protease domain, the kringle domain , and the growth factor domain . Urokinase is synthesized as a zymogen form prourokinase or single chain urokinase , and is activated by proteolytic cleavage between ... The most important inhibitors of urokinase are the serpin s plasminogen activator inhibitor 1 PAI ... matrix, urokinase is tethered to the cell membrane by its interaction to the urokinase ... stimulation, and red arrows inhibition. Urokinase and cancer Elevated gene expression expression levels of urokinase and several other components of the plasminogen activation system are found to be correlated ... activation facilitates tissue invasion and, thus, contributes to metastasis . This makes urokinase an attractive ... of these agents. Through its interaction with the urokinase receptor , urokinase affects several .... Clinical applications Urokinase is used clinically as a thrombolysis thrombolytic agent in the treatment ... of complicated pleural effusions and empyemas. Urokinase is presently marketed as Kinlytic sup ... Category EC 3.4.21 de Urokinase es Uroquinasa fa fr Urokinase it Attivatore dell u plasminogeno ... more details
PBB geneid 5329 The Urokinase receptor , also known as Urokinase uPA receptor or uPAR or CD87 C luster of D ifferentiation 87 , is multidomain glycoprotein tethered to the cell membrane with a GPI anchor glycosylphosphotidylinositol GPI anchor. uPAR was originally identified as a saturable binding site for urokinase on the cell surface. Molecular characteristics uPAR consists of three different domains ... of the primary ligand, urokinase. It has been possible to express uPAR recombinantly in Chinese ... of the human urokinase plasminogen activator receptor bound to an antagonist peptide journal EMBO ... ref and with its native ligand, urokinase. ref cite journal author Huai Q, Mazar AP, Kuo A, et al. title Structure of human urokinase plasminogen activator in complex with its receptor journal ... ligand urokinase , uPAR interacts with several other proteins , among others vitronectin , the uPAR ... binds urokinase and thus restricts plasminogen activation to the immediate vicinity of the cell membrane ... 27&issue 3&spage 157 ref Interactions Urokinase receptor has been shown to Protein protein interaction ... RA, Farquhar MG year 2001 month May title Direct binding of occupied urokinase receptor uPAR to LDL receptor related protein is required for endocytosis of uPAR and regulation of cell surface urokinase ... also Cancer Cluster of differentiation Metastasis Plasmin Plasminogen activation system Urokinase suPAR ... M title Structure function relationships in the interaction between the urokinase type plasminogen ... PBB Further reading citations cite journal author Kj ller L title The urokinase plasminogen activator ... T, Kanse SM, May AE, Preissner KT title Haemostatic factors occupy new territory the role of the urokinase ... H, J rgensen TJ, et al. title Structural analysis of the interaction between urokinase type plasminogen ... author Alfano M, Sidenius N, Blasi F, Poli G title The role of urokinase type plasminogen activator .... title The urokinase plasminogen activator and its receptor role in cell growth and apoptosis. journal ... more details
Wikify date April 2012 Orphan date April 2012 uPARAP , also known as Endo180 , is a membrane protein involved in turnover of extracellular matrix. The name is an acronym for Urokinase receptor urokinase type Plasminogen Activator Receptor Associated Protein. Loss of the uPARAP encoding gene MRC2 has been shown to cause Crooked Tail Disease in Belgian Blue Belgian Blue Cattle . References The urokinase receptor uPAR and the uPAR associated protein uPARAP Endo180 membrane proteins engaged in matrix turnover during tissue remodeling. Behrendt N. Biol Chem. 2004 Feb 385 2 103 36. Balancing selection of a frame shift mutation in the MRC2 gene accounts for the outbreak of the Crooked Tail Syndrome in Belgian Blue Cattle. Fasquelle C, Sartelet A, Li W, Dive M, Tamma N, Michaux C, Druet T, Huijbers IJ, Isacke CM, Coppieters W, Georges M, Charlier C. PLoS Genet. 2009 Sep 5 9 e1000666. Epub 2009 Sep 25. Category Proteins protein stub ... more details
Plasminogen activators can refer to Tissue plasminogen activator Urinary plasminogen activator also known as urokinase disambig Short pages monitor This long comment was added to the page to prevent it being listed on Special Shortpages. It and the accompanying monitoring template were generated via Template Longcomment. Please do not remove the monitor template without removing the comment as well. ... more details
Hementin is an anticoagulant protease from the salivary gland s of the giant Amazon region Amazon leech Haementeria ghilianii . Hementin dissolves a type of platelet rich blood clot which cannot be dissolved by other well used drugs like streptokinase and urokinase. External links http www.ncbi.nlm.nih.gov entrez query.fcgi?cmd Retrieve&db PubMed&list uids 6361187&dopt Abstract PubMed abstract Category Anticoagulants biochem stub ... more details
Unreferenced stub auto yes date December 2009 Image Fibrinolysis.png thumb 400px Fibrinolysis A plasminogen activator is a serine protease which converts plasminogen to plasmin, thus promoting fibrinolysis . Types include Tissue plasminogen activator Urokinase It is inhibited by plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 . Serine endopeptidases Antithrombotics Category Hematology DEFAULTSORT Plasminogen Activator blood drug stub pt Ativador do plasminog nio ... more details
barelinks date May 2011 suPAR , soluble urokinase type plasminogen activator receptor, NCBI Accession no. AAK31795 is the soluble form of uPAR . uPAR is a membrane bound receptor for uPA, otherwise known as urokinase . suPAR results from the cleavage and release of membrane bound uPAR. suPAR concentration positively correlates to the activation level of the immune system and is present in blood plasma plasma , urine , blood , blood serum serum , and cerebrospinal fluid . ref name SuPAR The Molecular Crystal Ball Thun , Maria, Betina Macho, and Jesper Eugen Olsen. SuPAR The Molecular Crystal Ball. Disease Markers 27 2009 157 72. ref Molecular characteristics suPAR has a secondary structure of 17 anti parallel beta sheets sheets with 3 short alpha helix helices . There are three homologous domains of suPAR DI, DII, and DIII. In the comparison of cDNA sequences, DI differs from DII and DIII in its primary structure primary and tertiary structure tertiary structure, causing its distinct ligand binding properties. ref name SuPAR The Molecular Crystal Ball ref M. Huang, A. P. Mazar, G. Parry, A. A. R. Higazi, A. Kuo and D. B. Cines. Crystallization of soluble urokinase receptor suPAR in complex with urokinase amino terminal fragment 1 143 . Acta Crystallographica 2005 D61 6 , 697 700. ref The gpi anchor GPI anchor links uPAR to the cell membrane making it available for urokinase uPA binding. When uPA is bound to the receptor, there is cleavage between the GPI anchor and DIII, forming suPAR. ref http www.suparnostic.com index.php whatsupar ref There are three different suPAR forms suPAR small I III small , suPAR small II III small , and suPAR small I small . Of these three forms suPAR small II III small is known to be a chemotactic agent for promoting the immune system. ref name SuPAR The Molecular Crystal Ball Application suPAR is a biomarker for activation of the inflammation ... al. Circulating Soluble Urokinase Plasminogen Activator Receptor Predicts Cancer, Cardiovascular Disease ... more details
mergeto Urokinase discussion Talk Urokinase date January 2010 PBB geneid 5328 Urokinase type plasminogen activator is an enzyme that in humans is encoded by the PLAU gene . ref name pmid2415429 cite journal author Nagai M, Hiramatsu R, Kaneda T, Hayasuke N, Arimura H, Nishida M, Suyama T title Molecular cloning of cDNA coding for human preprourokinase journal Gene volume 36 issue 1 2 pages 183 8 year 1985 month Dec pmid 2415429 pmc doi 10.1016 0378 1119 85 90084 8 ref The PBB Summary template is automatically maintained by Protein Box Bot. See Template PBB Controls to Stop updates. PBB Summary section title summary text This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late onset Alzheimer disease and also with decreased affinity for fibrin binding. The protein encoded by this gene converts plasminogen to plasmin by specific cleavage of an Arg Val bond in plasminogen. This gene s proprotein is cleaved at a Lys Ile bond by plasmin to form a two chain derivative in which a single disulfide bond connects the amino terminal A chain to the catalytically active, carboxy terminal B chain. This two chain derivative is also called HMW uPA high molecular weight uPA . HMW uPA can be further processed into LMW uPA low molecular weight uPA by cleavage of chain A into a short chain A A1 and an amino terminal fragment. LMW uPA is proteolytically ..., urokinase url http www.ncbi.nlm.nih.gov sites entrez?Db gene&Cmd ShowDetailView&TermToSearch ... between urokinase and plasma protein C inhibitor in vitro and in vivo journal Blood volume 74 issue ... H, J rgensen TJ, et al. title Structural analysis of the interaction between urokinase type plasminogen ... author Alfano M, Sidenius N, Blasi F, Poli G title The role of urokinase type plasminogen activator ... al. title Urokinase type plasminogen activator uPA and its inhibitor PAI I novel tumor derived factors ... more details
About the cancer cell PC3 PC3 PC 3 and DU145 human prostate cancer Cell culture Isolation of cells cell lines are the classical cell lines of prostatic cancer. ref cite journal author Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D title DU 145 and PC 3 human prostate cancer cell lines express androgen receptor implications for the androgen receptor functions and regulation journal FEBS Lett. volume 580 issue 9 pages 2294 300 year 2006 month April pmid 16580667 doi 10.1016 j.febslet.2006.03.041 url ref PC3 cells have high metastasis metastatic potential compared to DU145 cells which have a moderate metastatic potential. ref cite journal author Pulukuri SM, Gondi CS, Lakka SS, et al. title RNA interference directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo journal J. Biol. Chem. volume 280 issue 43 pages 36529 40 year 2005 month October pmid 16127174 pmc 1351057 doi 10.1074 jbc.M503111200 url ref PC3 cell lines were originally derived from advanced androgen independent bone metastasis metastasized prostate cancer. PC3 have low testosterone 5 alpha reductase activity, express PSA Prostate Specific Antigen and are PSMA negative Prostate specific membrane antigen . ref cite journal last Ghosh first Arundhati coauthors Xinning Wang, Eric Klein, and Warren D.W. Heston title Novel role of prostate specific membrane antigen in suppressing prostate cancer invasiveness. journal Cancer Research date 1 year 2005 month Feb volume 65 issue 3 pages 727 31 pmid 15705868 url http www.ncbi.nlm.nih.gov pubmed?term Novel 20Role 20of 20Prostate Specific 20Membrane 20Antigen 20in 20Suppressing 20Prostate 20Cancer 20Invasiveness accessdate 1 February 2012 ref References reflist Category Cell lines Category Cancer research Category Urology cell biology stub ... more details
DU145 DU 145 and PC3 human prostate cancer Cell culture Isolation of cells cell lines are the classical cell lines of prostatic cancer ref cite journal author Alimirah F, Chen J, Basrawala Z, Xin H, Choubey D title DU 145 and PC 3 human prostate cancer cell lines express androgen receptor implications for the androgen receptor functions and regulation journal FEBS Lett. volume 580 issue 9 pages 2294 300 year 2006 month April pmid 16580667 doi 10.1016 j.febslet.2006.03.041 url ref . DU145 cells have moderate metastasis metastatic potential compared to PC3 cells which have high metastatic potential ref cite journal author Pulukuri SM, Gondi CS, Lakka SS, et al title RNA interference directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo journal J. Biol. Chem. volume 280 issue 43 pages 36529 40 year 2005 month October pmid 16127174 pmc 1351057 doi 10.1074 jbc.M503111200 url http www.jbc.org cgi content full 280 43 36529 ref . The DU145 cell line was derived from brain metastasis. DU145 are not hormone sensitive and don t express PSA Prostate Specific Antigen . References Reflist cite journal author Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF title Isolation of a human prostate carcinoma cell line DU 145 journal Int. J. Cancer volume 21 issue 3 pages 274 81 year 1978 month March pmid 631930 doi 10.1002 ijc.2910210305 url Category Cell lines Category Cancer research Category Urology oncology stub ... more details
Orphan date February 2009 Argos is a secreted protein that is an inhibitor of the epidermal growth factor receptor EGFR pathway in Drosophila melanogaster . ref M. Freeman, C. Klambt, C. S. Goodman, G. M. Rubin, Cell 69, 963 1992 ref ref R. Schweitzer, R. Howes, R. Smith, B. Z. Shilo, M. Freeman, Nature 376, 699 1995 ref The name derives from the phenotype of mutant flies with eye defects and refers to Argus Panoptes . The mechanism by which Argos attenuates the EGFR pathway is by sequestration of ligand and not by direct interaction with the receptor. ref cite doi 10.1038 nature02840 ref Argos binds to the epidermal growth factor domain of the Drosophila ligand Spitz protein Spitz and prevents its interaction with the EGFR. Argos represents the first example of ligand sequestration as a mechanism of inhibition in the ErbB EGFR family. Crystallographic studies ref cite doi 10.1038 nature06978 ref reveal that Argos does not contain an EGF domain as originally expected. Rather, Argos is composed of 3 separate domains that have homology to one another, termed the Argos domain. The Argos domain has features in common with the three finger toxin fold that is found in a number of proteins including TGF beta receptor s and the urokinase receptor urokinase uPA receptor . Thus, the EGF decoy receptor Argos shares structural homology to receptors from the TGF beta and uPA families. A yet to be discovered human Argos may be found among related structures. The structure of Argos in complex with an EGFR ligand can be found at the Protein Data Bank under code http www.rcsb.org pdb explore explore.do?structureId 3C9A 3C9A . See also EGFR inhibitor References references Category Proteins protein stub ... more details
urokinase plasminogen activator gene ref Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Paterson AD, Rommens JM, Bharaj B, Blavignac ... more details
urokinase type plasminogen activator receptor are increased in patients with malaria and are associated ... CNS infection CNS infections ref Soluble urokinase receptor uPAR, CD 87 is present in serum and cerebrospinal .... 2002. Soluble urokinase receptor uPAR, CD 87 is present in serum and cerebrospinal fluid in patients ..., Menshikov MY. 2010. Release of the soluble urokinase type plasminogen activator receptor suPAR by activated ... more details
receptor for urokinase type plasminogen activator journal J. Biol. Chem. volume 266 issue 12 pages ... domain of the cellular receptor for human urokinase type plasminogen activator. A domain structure ... at Protein Reviews On The Web http mpr.nci.nih.gov prow . Subfamilies Urokinase plasminogen activator ... more details
List of drugs U U u U Cort U Gencin ubenimex International Nonproprietary Name INN ubidecarenone International Nonproprietary Name INN ubisindine International Nonproprietary Name INN ublituximab International Nonproprietary Name INN Ucephan udenafil International Nonproprietary Name INN , United States Adopted Name USAN ufenamate International Nonproprietary Name INN ufiprazole International Nonproprietary Name INN ularitide International Nonproprietary Name INN Ulcerease uldazepam International Nonproprietary Name INN ulimorelin United States Adopted Name USAN , International Nonproprietary Name INN ulipristal United States Adopted Name USAN Ulo ulobetasol International Nonproprietary Name INN Uloric Ultane Ultiva Ultra Technekow Fm Ultracef Ultracet Ultragris Ultralente Ultram Ultramop Ultraquin Ultrase Ultratag Ultravate Ultravist umeclidinium bromide United States Adopted Name USAN umespirone International Nonproprietary Name INN umifenovir International Nonproprietary Name INN umirolimus International Nonproprietary Name INN Unasyn Unguentine Uni Decon Uni Dur Uni Fed Uni Pro Uni tussin Unidet Unipen Uniphyl Unipres Uniretic Unisom Unitensen Unithroid Univasc Univol unoprostone International Nonproprietary Name INN upamostat International Nonproprietary Name INN upenazime International Nonproprietary Name INN Urabeth Uracil Mustard Capsules Roberts uramustine International Nonproprietary Name INN urapidil International Nonproprietary Name INN Urasal Ureaphil Urecholine uredepa International Nonproprietary Name INN uredofos International Nonproprietary Name INN urefibrate International Nonproprietary Name INN urelumab United States Adopted Name USAN Uremol Urese urethane International Nonproprietary Name INN Urex Uri Tet uridine triacetate International Nonproprietary Name INN Urisec Urised Urispas Uristat Urobak Urodine urofollitropin International Nonproprietary Name INN urokinase alfa International Nonproprietary Name INN urokinase International Nonproprieta ... more details
association for people interested in usability As the abbreviation uPA Urokinase , a serine protease enzyme, also known as urokinase type Plasminogen Activator or uPA disambig cs Upa de UPA ... more details
, Wun TC, Behrendt N, et al. title Inhibition of receptor bound urokinase by plasminogen activator inhibitors ... author Estreicher A, M hlhauser J, Carpentier JL, et al. title The receptor for urokinase type ... JA, Alexander SJ, Horton KW, et al. title Chromosomal organization and localization of the human urokinase ... P, Montuori N, Vassalli JD, Rossi G title Processing of complex between urokinase and its type 2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity. journal FEBS Lett ... H title Expression and localization of the urokinase type plasminogen activator receptor uPAR in the human ... more details
Thrombolytic drugs are used in medicine to dissolve thrombus blood clots in a procedure termed thrombolysis . They limit the damage caused by the blockage of the blood vessel . Uses Thrombolysis is used in myocardial infarction heart attack , Stroke Ischemic thromboembolic strokes , deep vein thrombosis and pulmonary embolism to clear a blocked artery and avoid permanent damage to the perfused see perfusion tissue e.g. myocardium , human brain brain , human leg leg and death . A less frequent use is to clear blocked catheter s that are used in long term medical therapy. Thrombolytic therapy in Stroke Hemorrhagic hemorrhagic stroke s is contraindicated , as its use in that situation would prolong bleeding into the intracranial space and cause further damage. Bleeding worksheet Members The thrombolytic drugs include tissue plasminogen activator t PA alteplase Activase reteplase Retavase tenecteplase TNKase anistreplase Eminase streptokinase Kabikinase , Streptase urokinase Abbokinase These drugs are most effective if administered immediately after it has been determined they are clinically appropriate. The advantage of administration is highest within the first sixty minutes, but may extend up to six hours after the start of symptoms. The drugs are often given in combination with intravenous heparin , or low molecular weight heparin , which are anticoagulant drug s. Side effects Hemorrhagic stroke is a rare but serious complication of thrombolytic therapy. If a patient has had thrombolysis before, an allergy against the thrombolytic drug may have developed especially after streptokinase . If the symptoms are mild, the infusion is stopped and the patient is commenced on an antihistamine before infusion is recommenced. Anaphylaxis generally requires immediate cessation of thrombolysis. See also thrombolysis anticoagulant drug s antiplatelet drug s antiaggregants References Reflist Antithrombotics Major Drug Groups DEFAULTSORT Thrombolytic Drug Category Drugs it Tromboli ... more details
Drugbox verifiedrevid 464387412 IUPAC name image Clinical data tradename pregnancy AU A B1 B2 B3 C D X pregnancy US A B C D X pregnancy category legal AU Unscheduled S2 S3 S4 S5 S6 S7 S8 S9 legal CA Schedule I, II, III, IV, V, VI, VII, VIII legal UK GSL P POM CD Class A, B, C legal US OTC Rx only Schedule I, II, III, IV, V legal status routes of administration Pharmacokinetic data bioavailability protein bound metabolism elimination half life excretion Identifiers CAS number Ref cascite correct ?? CAS number ATC prefix B01 ATC suffix AD08 PubChem DrugBank Ref drugbankcite correct drugbank DrugBank ChemSpiderID Ref chemspidercite correct chemspider ChemSpiderID NA Chemical data chemical formula molecular weight Saruplase is a fibrinolytic enzyme. ref name pmid10608024 cite journal author B r FW, Vermeer F, Michels R, et al. title Saruplase in Myocardial Infarction journal J. Thromb. Thrombolysis volume 2 issue 3 pages 195 204 year 1995 pmid 10608024 doi url ref It is closely related to urokinase . ref name pmid15992082 cite journal author Moser M, Bode C title Pharmacology and clinical trial results of saruplase scuPA in acute myocardial infarction journal Expert Opin Investig Drugs volume 8 issue 3 pages 329 35 year 1999 month March pmid 15992082 doi 10.1517 13543784.8.3.329 url ref References reflist External links MeshName Saruplase Antithrombotics Category Antithrombotic enzymes blood drug stub pt Saruplase ... more details
activated, it breaks down the fibrin mesh. t PA and urokinase are themselves inhibited by plasminogen ... activator tPA and urokinase. Alpha 2 antiplasmin and alpha 2 macroglobulin inactivate plasmin. Plasmin ... more details
, urokinase, and coagulation factor XII journal J. Mol. Evol. volume 26 issue 4 pages 358 369 year 1987 ... including prothrombin and urokinase type plasminogen activator, which are serine proteases belonging ... more details
LDL receptor related protein 1B impairs urokinase receptor regeneration on the cell surface and inhibits ... cells by reducing membrane localization of urokinase and PDGF receptors journal Arterioscler. Thromb ... more details
, urokinase plasminogen activator uPA , kallikrein , and factor XII Hageman factor . Fibrin is a cofactor for plasminogen activation by tissue plasminogen activator. urokinase receptor Urokinase plasminogen activator receptor uPAR is a cofactor for plasminogen activation by urokinase plasminogen activator ... more details
Encyclopedia
top
